Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2021 ASCO Annual Meeting

NEXT STORY
BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
PREV STORY
Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kura Oncology to Report Third Quarter 2020 Financial Results

author_avatar
NASDAQ Market News

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

author_avatar
NASDAQ Market News

Signature Resources Further Increases Its Lingman Lake Project Land Package in the Prolific Red Lake Geologic District

author_avatar
NASDAQ Market News